**FOI Ref: 6326**

**Category(ies): Clinical - Drugs**

**Subject: Lung Cancer Treatment**

**Date Received: 01/04/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:   * Afatinib * Alectinib * Atezolizumab monotherapy * Atezolizumab in combination * Bevacizumab * Brigatinib * Capmatenib * Ceritinib * Crizotinib * Dacomitinib * Dabrafenib with Trametinib * Docetaxel monotherapy * Durvalumab * Erlotinib * Gefitinib * Gemcitabine * Nintedanib with Docetaxel * Nivolumab * Osimertinib * Paclitaxel * Pembrolizumab monotherapy * Pembrolizumab in combination * Pemetrexed with Carboplatin/Cisplatin * Tepotinib * Vinorelbine with Cisplatin/Carboplatin * Any other SACT * Palliative care only | Regarding Palliative care only. 0 – Zero patients.  Systemic Anti-Cancer Therapy for Lung cancer patients is delivered by Weston Park; therefore, we are unable to further answer this request.  The request would need to go to Sheffield Teaching Hospitals who can be contacted via email at [sth.foi@nhs.net](mailto:sth.foi@nhs.net) |